Progenics Pharmaceuticals Presents Updated Data From Phase 1 Study of PSMA ADC

[at noodls] – – Outcomes From Clinical Study in Prostate Cancer Presented at Genitourinary Cancers Symposium – TARRYTOWN, N.Y., Feb. 14, 2013 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today reported … more

View todays social media effects on PGNX

View the latest stocks trending across Twitter. Click to view dashboard

See who Progenics is hiring next, click here to view